Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Language: English
    In: Progressive Neuroblastoma, 2015, Vol.20, p.1-9
    Description: Abstract Progressive neuroblastoma has a high risk of disease recurrence despite cancer treatment. Most patients can be identified at the time of diagnosis either by age over 18 months and the presence of distant metastases, or by amplification of the oncogene MYCN . As the body of knowledge concerning molecular mechanisms of cancer development and progression grows, molecular markers will increasingly substitute clinical factors for precise classification of patients with a high risk of disease progression. Successful treatment of high-risk neuroblastoma patients remains a challenge. State-of-the-art multimodality treatment of high-risk neuroblastoma patients includes intensive induction chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation, external beam radiation therapy, metaiodobenzylguanidine therapy, surgery and postconsolidation therapy such as isotretinoin or immunotherapy. The value of high-dose metaiodobenzylguanidine therapy and extensive surgery have not yet been proven by prospective trials. Although multimodality treatment has improved the outcome of high-risk neuroblastoma patients worldwide, the majority of patients will experience recurrence of disease. Long-term survivors of high-risk neuroblastoma face a considerable risk of a second malignant disease and treatment-induced chronic health conditions such as hypothyroidism and hearing impairment. © 2015 S. Karger AG, Basel
    ISBN: 978-3-318-05496-5
    ISSN: 1017-5989
    E-ISSN: 1662-3886
    Source: Karger Book Series
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Nature, 2004, Vol.427(6973), p.445
    Description: Bacterioplankton phylotypes of alpha -Proteobacteria have been detected in various marine regions, but systematic biogeographical studies of their global distribution are missing. alpha -Proteobacteria comprise one of the largest fractions of heterotrophic marine bacteria and include two clades, SAR11 and Roseobacter, which account for 26 and 16% of 16S ribosomal RNA gene clones retrieved from marine bacterioplankton. The SAR11 clade attracted much interest because related 16S rRNA gene clones were among the first groups of marine bacteria to be identified by cultivation-independent approaches and appear to dominate subtropical surface bacterioplankton communities. Here we report on the global distribution of a newly discovered cluster affiliated to the Roseobacter clade, comprising only as-yet-uncultured phylotypes. Bacteria of this cluster occur from temperate to polar regions with highest abundance in the Southern Ocean, but not in tropical and subtropical regions. Between the south Atlantic subtropical front and Antarctica, we detected two distinct phylotypes, one north and one south of the polar front, indicating that two adjacent but different oceanic provinces allow the persistence of distinct but closely related phylotypes. These results suggest that the global distribution of major marine bacterioplankton components is related to oceanic water masses and controlled by their environmental and biogeochemical properties.
    Keywords: Phylogeny ; Water Masses ; Biogeography ; Ecological Distribution ; Phenotypes ; Faunal Provinces ; Nannoplankton ; Heterotrophic Organisms ; Latitudinal Variations ; Microorganisms ; DNA ; Polar Waters ; Temperate Zones ; Marine Microorganisms ; Biogeochemistry ; Ecological Distribution ; Distribution ; Rrna 16s ; Phenotypes ; Bacterioplankton ; Roseobacter ; Proteobacteria ; Marine ; Water ; Plankton ; Ecology/Community Studies ; Microorganisms ; Genetics and Evolution ; Viruses, Bacteria, Protists, Fungi and Plants ; Bacterioplankton ; Rrna 16s;
    ISSN: 0028-0836
    E-ISSN: 14764687
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Developmental Medicine & Child Neurology, April 2012, Vol.54(4), pp.347-352
    Description: Prospective trials on neuroblastoma‐induced myelopathy are lacking. Therefore, we retrospectively analysed patients in four national neuroblastoma trials. Neuroblastoma patients diagnosed between August 1989 and December 2008 were included. Clinical and molecular data were available in the national trials database. Additional details on neurological findings, treatment, and outcome were collected using a questionnaire. Among 2603 patients, 122 (61 males and 61 females) had symptoms of spinal cord compression (SCC), and 99 of these were included in the final long‐term analysis. The survival of patients with symptoms of SCC was better than that of patients without symptoms. Patients first presented with lower extremity motor impairment (95%), impaired cutaneous sensibility (58%), neuropathic pain (56%), bladder dysfunction (44%), and/or constipation (34%). Symptoms improved after first‐line neurosurgery in 36 out of 52 patients and after first line chemotherapy in 30 out of 47 patients (=0.77). After a median observation time of 8 years 1 month (range 1mo–19y 6mo), 71 out of 99 patients still had residual impairments: motor impairment (43%), scoliosis (31%), impaired bladder function (26%), constipation (19%), impaired cutaneous sensibility (17%), growth delay (14%), and neuropathic pain (5%). The initial treatment had no clear impact on the frequency of late effects. This retrospective analysis showed no clear advantage of either first‐line neurosurgery or chemotherapy and that most patients still exhibit residual symptoms and require specialized care.
    Keywords: Medicine;
    ISSN: 0012-1622
    E-ISSN: 1469-8749
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: British journal of cancer, August 2018, Vol.119(3), pp.282-290
    Description: This study was done to investigate the long-term event free and overall survival of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), compared to maintenance chemotherapy (MT). Patterns of recurrences and late sequelae of both arms were analysed. A randomised open label trial was conducted nationwide during 1997-2004 in Germany and Switzerland. 295 patients with high-risk neuroblastoma were randomly assigned to high-dose chemotherapy with autologous stem cell transplantation (ASCT) or maintenance chemotherapy (MT) for consolidation. Analyses were done by intention-to-treat (ITT: ASCT/MT N = 149/146), as treated (AT: N = 110/102), and treated as randomised (TAR: N = 75/70). The event free survival was superior for the patients receiving ASCT compared to patients treated with MT in all three cohorts (hazard ratio [HR] for ITT 1.39, 95% confidence interval (CI) 1.05-1.85, P = 0.022, HR for AT 1.75, CI 1.24-2.47, P = 0.001; HR for TAR 2.07, CI 1.36-3.16, P = 0.001). Overall survival was also in favour of the ASCT groups (ITT: P = 0.075; AT: P = 0.017; TAR: P = 0.005). The frequencies of late sequelae were not different except for focal nodular hyperplasia of the liver observed more frequently in the ASCT arm. High-dose chemotherapy with autologous stem cell transplantation had a better long-term outcome compared to maintenance chemotherapy.
    Keywords: Transplantation, Autologous ; Maintenance Chemotherapy -- Methods ; Neoplasm Recurrence, Local -- Therapy ; Neuroblastoma -- Therapy
    ISSN: 00070920
    E-ISSN: 1532-1827
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Meteorology and Atmospheric Physics, 2013, Vol.121(1), pp.39-53
    Description: Inspired by the framework of the Coordinated Regional Climate Downscaling Experiment (CORDEX), the hindcast (1971–2000) and projection (2021–2050) simulations based on a resolution of $$0.44^\circ$$ over the East Asia domain are performed with the regional climate model COSMO-CLM (CCLM). The simulations are driven by ERA-40 reanalysis data and output of the global climate model ECHAM5. This is the first time that the CCLM is adapted and evaluated for the East Asia Monsoon region; the setup is considered a starting point for further improvements in this region by the CCLM community. The evaluation results show that the CCLM is able to reasonably capture the climate features in this region, especially the monsoon dynamics on small scales. However, total precipitation in the northern part of the domain, over the Tibetan Plateau, and over east Indonesia has a pronounced wet bias. The projected climate change under the A1B scenario indicates an overall annual surface temperature increase of 1–2 K, but no significant precipitation changes.
    Keywords: Global Temperature Changes -- Analysis ; Rain -- Analysis;
    ISSN: 0177-7971
    E-ISSN: 1436-5065
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: BMC Cancer, Jan 18, 2011, Vol.11, p.21
    Description: Background The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort. Methods A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls. Results The median observation time was 11.11 years. The nine-year event-free survival rates were 41 [+ -] 4%, 31 [+ -] 5%, and 32 [+ -] 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 [+ -] 4%) compared to NB90 MT (34 [+ -] 5%, p = 0.026) and to no consolidation (35 [+ -] 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found. Conclusions Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
    Keywords: Neuroblastoma -- Care And Treatment ; Neuroblastoma -- Patient Outcomes ; Neuroblastoma -- Research ; Immunotherapy -- Patient Outcomes ; Immunotherapy -- Research
    ISSN: 1471-2407
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: BMC Cancer, Jan 18, 2011, Vol.11, p.21
    Description: Background The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort. Methods A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls. Results The median observation time was 11.11 years. The nine-year event-free survival rates were 41 [+ -] 4%, 31 [+ -] 5%, and 32 [+ -] 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 [+ -] 4%) compared to NB90 MT (34 [+ -] 5%, p = 0.026) and to no consolidation (35 [+ -] 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found. Conclusions Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
    Keywords: Neuroblastoma -- Care And Treatment ; Neuroblastoma -- Patient Outcomes ; Neuroblastoma -- Research ; Immunotherapy -- Patient Outcomes ; Immunotherapy -- Research
    ISSN: 1471-2407
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: The Journal of Pediatrics, September 2017, Vol.188, pp.294-298
    Description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jpeds.2017.05.051 Byline: Toby Trahair, Stefania Sorrentino, Susan J. Russell, Hugo Sampaio, Laurent Selek, Dominique Plantaz, Claire Freycon, Thorsten Simon, Kathelijne Kraal, Maja Beck-Popovic, Riccardo Haupt, Shifra Ash, Bruno De Bernardi Article History: Received 13 October 2016; Revised 5 May 2017; Accepted 18 May 2017 Article Note: (footnote) The authors declare no conflicts of interest.
    Keywords: Pediatric Oncology ; Neuroblastoma ; Spinal Cord Compression ; Medicine
    ISSN: 0022-3476
    E-ISSN: 1097-6833
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: BMC Cancer, 01 January 2011, Vol.11(1), p.21
    Description: Abstract Background The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort. Methods A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls. Results The median observation time was 11.11 years. The nine-year event-free survival rates were 41 ± 4%, 31 ± 5%, and 32 ± 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ± 5%, p = 0.026) and to no consolidation (35 ± 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found. Conclusions Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
    Keywords: Medicine
    ISSN: 1471-2407
    E-ISSN: 1471-2407
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Journal of Bacteriology, 2011, Vol. 193(23), p.6576
    Description: The production of N-acyl homoserine lactones (AHLs) is widely distributed within the marine Roseobacter clade, and it was proposed that AHL-mediated quorum sensing (QS) is one of the most common cell-to-cell communication mechanisms in roseobacters. The traits regulated by AHL-mediated QS are yet not known for members of the Roseobacter clade, but production of the antibiotic tropodithietic acid (TDA) was supposed to be controlled by AHL-mediated QS in Phaeobacter spp. We describe here for the first time the functional role of luxR and luxI homologous genes of an organism of the Roseobacter clade, i.e., pgaR and pgaI in Phaeobacter gallaeciensis. Our results demonstrate that the AHL synthase gene pgaI is responsible for production of N-3-hydroxydecanoylhomoserine lactone (3OH[C.sub.10]-HSL). Insertion mutants of pgaI andpgaR are both deficient in TDA biosynthesis and the formation of a yellow-brown pigment when grown in liquid marine broth medium. This indicates that in P. gallaeciensis the production of both secondary metabolites is controlled by AHLmediated QS. Quantitative real-time PCR showed that the transcription level of tdaA, which encodes an essential transcriptional regulator for TDA biosynthesis, decreased 28- and 51-fold in pgal and pgaR genetic backgrounds, respectively. These results suggest that both the response regulator PgaR and the 3OH[C.sub.10]-HSL produced by PgaI induce expression of tdaA, which in turn positively regulates expression of the tda genes. Moreover, we confirmed that TDA can also act as autoinducer in P. gallaeciensis, as previously described for Silicibacter sp. strain TM1040, but only in the presence of the response regulator PgaR. doi: 10.1128/JB.05818-11
    Keywords: Proteobacteria -- Genetic Aspects ; Proteobacteria -- Physiological Aspects ; Proteobacteria -- Research ; Quorum Sensing -- Research ; Lactones -- Physiological Aspects ; Lactones -- Research ; Metabolites -- Research;
    ISSN: 1098-5530
    ISSN: 10985530
    ISSN: 00219193
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages